

45. (New) A medicament comprising the polypeptide of claim 12.

46. (New) A method for treating a vertebrate with a Candida albicans associated disease comprising contacting the vertebrate with the medicament of claim 44.

47. (New) A method for detecting the presence of Candida albicans in a subject comprising the steps of contacting a sample to be tested with the antibody of claim 34 and detecting antibody binding to said sample.

48. (New) A kit for detecting Candida albicans infection comprising an antibody capable of binding to a polypeptide encoded by the nucleic acid molecules of claim 1.

REMARKS

Claims 18, 19, 20, 21, 27, 36, and 37 have been canceled. Claims 1-7, 9, 11, 12, 15, 17, 22-24, 26, 28, 30-35, and 38-40 have been amended solely to conform the claims to USPTO examination procedures, including correcting multiple dependencies. Claims 41-48 have been added in part as a result of removing the multiple dependencies originally present in Claims 1-40. No new matter has been added by these amendments and support for these amendments can be found throughout the specification and in the claims as originally filed.

A sequence listing has been provided along with the sequence listing in Computer Readable Form. The undersigned hereby states that the sequence content of the paper copy and the Computer Readable Form are identical.

Favorable consideration of this application is respectfully requested.

Respectfully submitted,

Myra H. McCormack
Myra H. McCormack
Attorney for Applicants
Reg. No. 36,602

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6814
Dated: February 14, 2001